Volume not the defining metric: Dosimetric benefits of adding supplemental interstitial needles for small volume cervical tumors.

Authors

Emily Smith, Nicholas Ngo, Thomas Niedermayr, Elizabeth Kidd

Published in

Journal of contemporary brachytherapy. Volume 18. Issue 2. Pages 147-153. Epub Jun 30, 2026.

Abstract

In brachytherapy for cervical cancer, previous data have demonstrated improved local control with adding supplementary interstitial needles for cervical tumors > 30 cm³ and increased D₉₀ to high-risk clinical target volume (HR-CTV) without increasing dose to adjacent normal tissues. Therefore, needles are more routinely added for larger volume tumors. At our institution, supplemental interstitial needles have routinely been used for all cervix cancer brachytherapy cases, even smaller volume tumors. This study aimed to identify the dosimetric advantages of supplementary interstitial needles for small volume cervix tumors.
Fifty-seven intracavity/interstitial (IC/IS) patients treated from November 2019 through November 2023 with HR-CTV < 30 cm³ at the first brachytherapy fraction were included. High-dose-rate (HDR) brachytherapy plans were re-optimized using an intracavitary applicator only, without needles, to improve coverage while maintaining similar minimum doses to the clinical plan for the most irradiated 2 cm³ of bladder, rectum, and bowel.
The median HR-CTV was 19.3 cm³ (range, 4.38-29.95 cm³). For a single-brachytherapy fraction per patient, the average volume of HR-CTV receiving 100% of the prescription dose (V₁₀₀) was 92.9% vs. 79.8% for IC/IS vs. no-needle plans, respectively (p < 0.0001). Normal tissue metrics for the rectum, bowel, and bladder showed no statistically significant difference between the two plans. Combining the external beam and extrapolated brachytherapy doses, the average HR-CTV dose received by 90% of the volume (D₉₀) was 90.1 Gy for IC/IS vs. 81.1 Gy for no-needle plans (p < 0.0001). Even for volumes < 20 cm³ (n = 32) and < 15 cm³ (n = 16), HR-CTV V₁₀₀ and D₉₀ were significantly improved with needles added (p < 0.0001).
These results suggest a significant dosimetric benefit of adding supplementary interstitial needles even for small volume cervical tumors, allowing enhanced dose shaping to improve HR-CTV coverage and achieving EMBRACE II target dosing goals, while maintaining normal tissue sparing.

PMID:
42488744
Bibliographic data and abstract were imported from PubMed on 23 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.